Treatment options after Osimertinib resistance

Osimertinib (Osimertinib) is a targeted drug used to treat non-small cell lung cancer with EGFR (epidermal growth factor receptor) mutations. Sometimes, however, patients may develop resistance to osimertinib. When a patient develops drug resistance, the best treatment option depends on individual circumstances, including the patient's genotype, the location and spread of the disease, the patient's overall health, and available medical resources.

For resistant lesions that occur only in local areas, surgical resection may be an option, which can help remove osimertinib-resistant tumors. For locally advanced or metastatic drug-resistant disease, radiation therapy can be used to slow disease progression and relieve symptoms, which can control the disease by destroying tumor cells. Chemotherapy drugs may be used as first-line treatment options after osimertinib resistance. Pemetrexed and platinum drugs (such as cisplatin or carboplatin) can be used in combination with osimertinib. Third-generation EGFR inhibitors similar to osimertinib, such as Ramatlitinib and Femelitnib, can also be used as treatment options after osimertinib resistance. These drugs can inhibit the growth of tumors caused by other EGFR mutations.

OsimertinibThe original drug has been launched in China and has entered the scope of medical insurance. Its name is Osimertinib Mesylate Tablets. The reimbursement ratio is different in different regions, and the price after reimbursement may be different. SpecificationThe price of 80mg*30 tablets per box is around RMB 5,000, which is relatively expensive. The original drug of Osimertinib has also been launched overseas, and there are also generics of Osimertinib produced in other countries. For example, the price of 80mg*30 tablets per box produced by Bangladesh Yaopin International is around RMB 850 (the price may fluctuate due to the exchange rate). The price is relatively cheap. The ingredients of the generic Osimertinib and the original drug are basically the same.